VIVANI MEDICAL INC
VANINASDAQTrading Snapshot
- Day Range
- $1.21 – $1.24
- 52-Week Range
- $0.92 – $1.92
- Volume
- $3.82B
- Avg Volume
- $3.02B
- Shares Outstanding
- 86.2M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $4M
- P/E Ratio
- -3.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +8.6%
Why Investors Own VANI
- ✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VIVANI MEDICAL INC
VANI
StockOtter · stockotter.spaceAbout VIVANI MEDICAL INC
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Vivani Medical Announces Participation in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utiliz
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company's implant technology.
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announ